Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator

Rodenhuis, S; van't Hek, L G; Vlasveld, L T; Kröger, R; Dubbelman, R; van Tol, R G
May 1993
Thorax;May1993, Vol. 48 Issue 5, p558
Academic Journal
No abstract available.


Related Articles

  • Thrombolytic Therapy for Adhesion of Percutaneous Central Venous Catheters to Vein Intima Associated With Malassezia furfur Infection. Nguyen, Son T; Lund, Carolyn H; Durand, David J // Journal of Perinatology;Jul2001, Vol. 21 Issue 5, p331 

    OBJECTIVE: To report our experience with thrombolytic agents in the management of two infants with silicone central venous catheters that had adhered to the vein wall as a result of infection with Malassezia furfur. STUDY DESIGN: Case review of two very low birth weight infants with adherent...

  • Treatment of Superior Mesenteric and Portal Vein Thrombosis with Direct Thrombolytic Infusion via an Operatively Placed Mesenteric Catheter. Kaplan, Jonathan L.; Weintraub, Sharon L.; Hunt, John P.; Gonzalez, Arturo; Lopera, Jorge; Brazzini, Augusto // American Surgeon;Jul2004, Vol. 70 Issue 7, p600 

    Acute superior mesenteric vein (SMV) and portal vein (PV) thrombosis can be a complication of hypercoagulable, inflammatory, or infectious states. It can also occur as a complication of medical or surgical intervention. Management of mesenteric and portal vein thrombosis includes both operative...

  • Endovascular treatment of postpartum deep venous thrombosis: report of three cases. Dumantepe, Mert; Arif, Tarhan Ibrahım; Ilhan, Yurdakul; Ozdemir, Arzu; Azmi, Ozler; Arif, Tarhan Ibrahım // Vascular;Dec2013, Vol. 21 Issue 6, p380 

    Pregnancy and the postpartum period are generally considered as contraindications for thrombolysis. We evaluate in this report the safety and effectiveness of using ultrasound-accelerated catheter-directed thrombolysis (UACDT) in treating three symptomatic postpartum deep vein thrombosis (DVT)....

  • Catheter-Related Thrombosis in Pediatrics.  // Pediatric Nursing;Mar/Apr2002, Vol. 28 Issue 2, p97 

    Focuses on the thrombotic complications that are seen when venous access devices are used in intravenous therapy as well as current treatment options using thrombolytic agents. Information on hemostasis and fibrinolysis; Discussion on catheter occlusion; Description on central vein thrombosis.

  • Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Nilsson, Inga Marie; Ljungner, Harald; Tengborn, Lilian // British Medical Journal (Clinical Research Edition);5/18/1985, Vol. 290 Issue 6480, p1453 

    Examines the fibrinolytic components after venous occlusion and concentration of tissue plasminogen in patients with deep vein thrombosis or pulmonary embolism. Role of fibrinolytic inhibitors on venous thrombosis; Determination of plasminogen activators; Measurement of tissue plasminogen...

  • Successful treatment of neonatal pulmonary thrombosis in congenital nephrotic syndrome. Makonkawkeyoon, Krit; Silvilairat, Suchaya; Chartapisak, Wattana // Cardiology in the Young;Apr2013, Vol. 23 Issue 2, p271 

    The incidence of neonatal thrombosis has been increasing in recent times because of the use of a central venous catheter. A treatment modality consisting of fibrinolytic agents has been administered for this life-threatening condition. This case report presents the successful management of a...

  • Clot-Breaking Drug Lowers Catheter Failure Risk. Charnow, Jody A. // Renal & Urology News;Apr2011, Vol. 10 Issue 4, p3 

    The article offers information on the use of recombinant tissue plasminogen activator (rt-PA) in decreasing the risk of catheter malfunction and bacteremia for central venous catheters in hemodialysis (HD) patients.

  • Intravitreal Tissue Plasminogen Activator for the Treatment of Central Retinal Vein Occlusion. Weizer, Jennifer S.; Fekrat, Sharon // Ophthalmic Surgery, Lasers & Imaging;Jul/Aug2003, Vol. 34 Issue 4, p350 

    A 58-year-old hypertensive man with a perfused central retinal vein occlusion of 21 days' duration received 50 µg of intravitreal recombinant tissue plasminogen activator in 0.1 cc. Best-corrected visual acuity improved 2 weeks after the injection. Optical coherence tomography and fluorescein...

  • Preventing dialysis catheter lumen occlusion: Preclot trial.  // British Journal of Hospital Medicine (17508460);Feb2011, Vol. 72 Issue 2, p71 

    The article reports a trial carried out on chronic haemodialysis patients with a newly inserted central venous haemodialysis catheter to find out whether substituting recombinant tissue plasminogen activator (rt-PA) for heparin once per week, as a catheter locking solution, would decrease the...

  • Two different mechanisms in patients with venous thromboses and defective fibrinolysis. Layer, G.T.; Burnand, K.G. // British Medical Journal (Clinical Research Edition);7/6/1985, Vol. 291 Issue 6487, p56 

    Focuses on the mechanisms in patients with venous thrombosis and defective fibrinolysis. Role of tissue plasminogen activator inhibitor in the pathogenesis of venous thrombosis; Localization of polyclonal antibodies to tissue plasminogen.


Read the Article


Sign out of this library

Other Topics